Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws
Authors:
- 5 January 2012
- journal article
- clinical trial
- Published by Springer Nature in Osteoporosis International
- Vol. 23 (11) , 2721-2725
Abstract
To review the effect of teriparatide as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws (BRONJ), we describe a series of cases of teriparatide therapy for the treatment of BRONJ and serial changes of serum osteoclacin (s-OC) and serum C-terminal telopeptide cross-link of type I collagen (s-CTX). Management of BRONJ is quite challenging and the currently recommended modalities for BRONJ are still suboptimal. For the improvement of bony remodeling, some clinicians advocated bisphosphonate holiday although validity of this drug holiday has been debated so far. Recently, the use of teriparatide was introduced in several cases, but the number of the publication is limited and mostly anecdotal so far. Bisphosphonate was suspended and teriparatide was given to six patients diagnosed with BRONJ by single bone specialist. Medical record review and interviews were carried out. S-CTX and s-OC were measured at the baseline, 2 months and 3 months later teriparatide therapy. The outcome of the treatment and the change of biochemical markers were compared. In all six patients, s-OC values were significantly elevated within 2 months after teriparatide treatment and the BRONJ lesions were healed. S-CTX values were also elevated in four patients, whereas those of the rest two patients stayed within minimal change. The change was marginally significant at 3 months. In terms of the multifactorial etiology of BRONJ, bone formation suppression was noticed in the patients. Based upon this finding, the short-term use of teriparatide might be beneficial to the resolution of BRONJ lesions by improving suppressed bone remodeling.Keywords
This publication has 21 references indexed in Scilit:
- Successful treatment of advanced bisphosphonate‐related osteonecrosis of the mandible with adjunctive teriparatide therapyHead & Neck, 2011
- Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers?Clinical Oral Implants Research, 2010
- Could teriparatide be the treatment for osteonecrosis of the jaws?Head & Neck, 2010
- Correlation Between Serum C-Terminal Cross-Linking Telopeptide of Type I Collagen and Staging of Oral Bisphosphonate-Related Osteonecrosis of the JawsJournal of Oral and Maxillofacial Surgery, 2009
- The Role of Surgical Resection in the Management of Bisphosphonate-Related Osteonecrosis of the JawsJournal of Oral and Maxillofacial Surgery, 2009
- Oral Bisphosphonate–Induced Osteonecrosis: Risk Factors, Prediction of Risk Using Serum CTX Testing, Prevention, and TreatmentJournal of Oral and Maxillofacial Surgery, 2008
- Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holidayOsteoporosis International, 2008
- Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker: reply to Yarom and EladOsteoporosis International, 2008
- Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal WomenNew England Journal of Medicine, 2004
- Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone StructureJournal of Bone and Mineral Research, 2003